News & Announcements

PHAR Projects Cost Savings from Hepatitis C Cures

Chronic Hepatitis C Virus (HCV) is a common infectious disease that affects 2.4 million people in the United States. The clinical and economic impact of HCV on the US healthcare system is significant. Direct-acting antiviral (DAA) treatments have been shown to provide a cure for HCV in most individuals, however there has been debate over… read more

PHAR LLC announces the appointment of Mallik Greene, BPharm, PhD, DBA to the position of Vice President, Health Economics and Outcomes Research

Los Angeles, CA and Boston, MA – July 18, 2019 – PHAR LLC (Los Angeles, CA and Boston, MA), a boutique health care consultancy dedicated to the practice of health economics and outcomes research, announces the appointment of Mallik Greene, BPharm, PhD, DBA to the position of Vice President for Health Economics and Outcomes Research (mgreene@pharllc.com)…. read more

Biased Estimates of New Drug Costs Miss by Billions

PHAR announced today the final results of a study, published in Current Medical Research and Opinion, which found that pre-launch predictions of the budget impact of newly developed drugs tended to be considerable overestimates of their actual sales. The study examined the accuracy of 25 publicly released predictions for the cost of drugs launched in… read more

bioTheranostics’ CancerTYPE ID® Molecular Test Is a Cost-Effective Approach to Standardizing Diagnosis & Improving Metastatic Cancer Care

A study completed by PHAR and researchers at bioTheranostics Inc found that use of bioTheranostics’ CancerTYPE ID® molecular test is a cost-effective approach to standardizing diagnostic methods for patients with metastatic tumors of uncertain origin while improving patient care. The study was the first of its kind to examine the implications of molecular classification in… read more